Issue 62, 2022

An active tumor-targeting organic photochemotherapy agent with naproxen for enhanced cancer therapy

Abstract

An active tumor-targeting organic photochemotherapy agent via the combination of a an organic photothermal material and a naproxen prodrug was developed to precisely kill cancer cells and suppress the inflammatory response induced by cell necrosis; in vitro, and in vivo experiments illustrated its low cytotoxicity and excellent tumor inhibitory effect.

Graphical abstract: An active tumor-targeting organic photochemotherapy agent with naproxen for enhanced cancer therapy

Supplementary files

Article information

Article type
Communication
Submitted
26 Mar 2022
Accepted
29 Jun 2022
First published
07 Jul 2022

Chem. Commun., 2022,58, 8682-8685

An active tumor-targeting organic photochemotherapy agent with naproxen for enhanced cancer therapy

C. Xu, J. Chang, Y. Li, K. Wang, W. Pan, H. Wang, N. Li and B. Tang, Chem. Commun., 2022, 58, 8682 DOI: 10.1039/D2CC01729F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements